Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Juanita Kcomt

Nephrology Willow Grove, PA Medical Doctor

NPI 1285744516 CMS profile 513181

735 Fitzwatertown Rd, #1, Willow Grove, PA 19090

Open in the dashboard

General payments

$2,420

102 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Juanita Kcomt of Willow Grove, PA is reported in the CMS Open Payments database as having received $2,420 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,111 39
2024 General $380 21
2023 General $254 14
2022 General $149 9
2021 General $117 7
2019 General $410 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Juanita Kcomt
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Juanita Kcomt were reported at $1,111. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Juanita Kcomt Nephrology median Middle half National median
2019 $410 $236 $90–$588 $163
2020 $0 $135 $46–$364 $114
2021 $117 $202 $67–$551 $132
2022 $149 $242 $77–$695 $149
2023 $254 $254 $84–$766 $160
2024 $380 $300 $99–$852 $164
2025 $1,111 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $435 19 payments
  2. Otsuka America Pharmaceutical, Inc. $248 5 payments
  3. Novo Nordisk Inc $230 6 payments
  4. Calliditas Therapeutics US Inc. $218 6 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $209 12 payments
  6. OPKO Pharmaceuticals, LLC $190 12 payments
  7. Akebia Therapeutics Inc $160 7 payments
  8. Corcept Therapeutics $102 4 payments
  9. Relypsa, Inc. $101 2 payments
  10. AstraZeneca Pharmaceuticals LP $84 5 payments
  11. Other $443 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,334 97 payments
  2. Education $86 5 payments
Products named General payments · program years 2019–2025
  1. Kerendia $209 12 payments
  2. Ozempic $207 5 payments
  3. TARPEYO $200 5 payments
  4. RAYALDEE $190 12 payments
  5. JYNARQUE $185 2 payments
  6. KRYSTEXXA $171 9 payments
  7. Vafseo $160 7 payments
  8. Parsabiv $126 8 payments
  9. EVENITY $119 1 payment
  10. Korlym $102 4 payments
  11. Other $603 28 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

701

Median for Endocrinology: 1,959

Drug cost

$190,327

Median for Endocrinology: $890,201

Branded share of claims

29.7%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Forteo Teriparatide Brand 21 $106,194
Tradjenta Linagliptin Brand 38 $27,495
Ozempic Semaglutide Brand 16 $14,927
Rayaldee Calcifediol Brand 11 $14,800
Clinolipid Fat Emulsion/Olive/Soy/Phospho Brand 37 $13,527
Humalog Insulin Lispro Brand 16 $3,256
Sevelamer Carbonate Generic 18 $2,212
Levothyroxine Sodium Generic 151 $1,886
Nifedipine Er Nifedipine Brand 58 $1,774
Hydrocortisone Generic 32 $1,730

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$153,266

Medicare's payments for the services billed

Medicare patients

558

Average age 71

Services billed

1,146

301 women, 257 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 64%
Arthritis 47%
Diabetes 46%
Ischemic heart disease 45%
Cancer 38%
Heart failure 34%
Depression 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $58
$58 — —
RAYALDEE
  • OPKO Pharmaceuticals, LLC $48
$48 11 —
Korlym
  • Corcept Therapeutics $45
$45 — —
Vafseo
  • AKEBIA THERAPEUTICS INC $37
$37 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record